Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.

A researcher at the lab filling in some test tubes © Oxford University Images

The agreement establishes the GSK-Oxford Cancer Immuno-Prevention Programme, aimed at exploring the potential of cancer prevention through vaccination.

The programme leverages the complementary expertise of GSK and Oxford in the science of the immune system, vaccine development and cancer biology. It is hoped that the insights generated through the programme into how cancer develops could inform new approaches to vaccination for cancer prevention, offering fresh hope in the fight against the disease.

The programme - which will be led by Professor Sarah Blagden in Oxford’s Department of Oncology, alongside Dr Timothy Clay and Dr Ramon Kemp at GSK - unites expertise from four departments across the University and builds on Oxford’s exceptional track record in vaccine development.

Professor Irene Tracey, Vice-Chancellor of the University of Oxford, said: 'This partnership represents a step forward in cancer research. By working with GSK to unite experts in clinical trials, immuno-oncology, vaccinology and precancer research from across the University of Oxford, we aim to unlock the potential of cancer vaccines and bring hope to patients worldwide.'

 

Read the full story on the University of Oxford website.